FDA: 25 Warning Letters to Telehealth GLP-1 Compounders

The U.S. Food and Drug Administration (FDA) issued 25 new warning letters to telehealth companies on June 15, 2026, targeting false or misleading promotional claims about compounded semaglutide and tirzepatide products. This marks the third major enforcement wave in less than a year.

What happened?

Following 55+ letters in September 2025 and 30 letters in March 2026, the FDA's June 2026 wave targets companies including Medica Weight Loss, Ready Med, and Clover Meds. The agency's core message: compounded drugs are not FDA-approved and have not undergone premarket review for safety, efficacy, or manufacturing quality.

Which claims are prohibited?

The FDA specifically flagged the following violations:

• Claims that compounded products are "equivalent" or "identical" to FDA-approved drugs like Ozempic, Wegovy, Mounjaro, or Zepbound
• Proprietary brand names suggesting FDA approval or review
• Statements that ingredients are "clinically studied" without disclosing the product's unapproved status
• Presenting compounded products as "generic" versions of brand-name medications

Why this matters for Peptipedia readers

Compounded GLP-1 products and research peptides often share similar distribution channels - telehealth platforms, online shops, and social media. The FDA warnings reveal a pattern: unapproved products marketed with medical-sounding promises. For context, see our coverage of the FDA's proposed ban on bulk compounding of semaglutide and tirzepatide and check the current vendor warning list for reported scam sellers.

What are the patient safety risks?

As of May 2026, the FDA had received over 1,700 adverse event reports associated with compounded semaglutide and tirzepatide. Issues include dosing errors, contamination, and lack of sterility. FDA Commissioner Marty Makary stated: "Compounded drugs can be important for overcoming shortages - but compounders should not try to circumvent FDA's approval process."

Not medical advice: This article is for informational purposes only and does not replace professional medical consultation. Always consult your healthcare provider regarding GLP-1 medications.